Retinal imaging technology that identifies risk for cardiovascular disease coming to US
Click Here to Manage Email Alerts
New Zealand-based Toku Eyes has announced a U.S. expansion of its retinal imaging ORAiCLE technology, which can detect risk for heart attack and stroke, by 2025.
According to a company press release, Toku Eyes will partner with EyeCheq and Unified-Imaging to launch the artificial intelligence-based technology, which can assess an individual’s risk for cardiovascular disease through a retinal scan, at more than 1,500 U.S. locations, including pharmacies and self-service retinal photo kiosks.
ORAiCLE uses a retinal image to calculate an individual’s risk for cardiovascular events like stroke or heart attack within 5 years by recognizing “minute changes in the blood vessels, capillaries, arteries” and more, the company stated in the release. The technology, which is currently being used in New Zealand and India to test for diabetes, also provides wellness advice and alerts for specialized, preventive care.
“By looking inside the eyes, we get an in‐depth view of what is happening inside the entire body to better assess the risk factors of each individual and identify high‐risk individuals before their condition worsens,” Ehsan Vaghefi, PhD, Toku Eyes co-founder and CEO, said in the release. “Our goal is to make health screening simple and easy to access for the entire population so we can get in front of underlying health risks and improve patient outcomes.”
Read more about
Click Here to Manage Email Alerts